NeuBase Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NBSE research report →
Price Chart
About the company
Operating as a pre-clinical biopharmaceutical company, NeuBase Therapeutics, Inc. is dedicated to pioneering therapeutic solutions for rare genetic disorders and various cancers stemming from aberrant genes. At the core of its approach is the proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform.
- CEO
- Todd P. Branning
- IPO
- 2004
- Employees
- 37
- HQ
- Pittsburgh, PA, US
Get TickerSpark's AI analysis on NBSE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.42M
- P/E
- -0.02
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 0.03
- EV/EBITDA
- 0.48
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -88.62%
- ROIC
- -114.15%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-1,262,512-119.4%
- Op Income
- $-33,318,339
- Net Income
- $-34,234,561-33.4%
- EPS
- $-21.08-12.1%
- OCF Growth
- -53.7%
- FCF Growth
- -45.2%
- 52W High
- $4.44
- 52W Low
- $0.36
- 50D MA
- $0.47
- 200D MA
- $0.72
- Beta
- 0.94
- RSI (14)
- 31
- Avg Volume
- 128.24K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Ohr said it is funded through the MAKO readout and expects topline Squalamine data in early 2018, while reporting a smaller fiscal 2017 loss and regained Nasdaq compliance.· December 15, 2017
- MAKO topline data for Squalamine is expected in early calendar 2018, almost a year earlier than originally planned.
- Management said the trial was prospectively enriched for patients most likely to benefit, based on Phase 2 analysis of occult CNV size.
- The company reported it is funded into April 2018, enough to complete the MAKO trial and data readout.
- Nasdaq compliance was regained after the stock traded above $1 for 10 consecutive days.
- Ohr continues active business development discussions with potential pharmaceutical partners ahead of the data readout.
For fiscal 2017, total operating expenses were approximately $23.8 million, down from approximately $24.6 million in fiscal 2016. The company reported a net loss of approximately $23.8 million, or $0.53 per share, compared with a net loss of approximately $25.8 million, or $0.82 per share in fiscal 2016. Cash and cash equivalents were approximately $12.8 million at September 30, 2017, versus approximately $12.5 million a year earlier. Management said it completed two financings in fiscal 2017, raising net proceeds of $6.8 million in December and $12.7 million in April, for a combined total of $19.5 million. Forward looking, the company said it is funded into April 2018, including completion of the MAKO clinical trial and the data readout.
Jason Slakter framed the quarter as a pivotal period for Ohr, with the company approaching MAKO topline results for Squalamine in wet AMD. He emphasized that the study design was informed by prior Phase 2 data and that patient selection was deliberately enriched to improve the odds of seeing benefit, which he said has de-risked the trial. He also highlighted the strategic decision to accelerate the readout and said the near-term data should support ongoing partnering discussions.
Sam Backenroth reported fiscal 2017 operating expenses of approximately $23.8 million, with $5.3 million in G&A, $17.4 million in R&D, and $1.2 million in depreciation and amortization. He noted the net loss improved to approximately $23.8 million, or $0.53 per share, from $25.8 million, or $0.82 per share in fiscal 2016. Cash and cash equivalents were approximately $12.8 million at September 30, 2017, and management said the company is funded into April 2018 after raising a combined net $19.5 million across two financings during fiscal 2017.
There was no Q&A on the call; management explicitly said it would not take questions because of the proximity of receiving MAKO data. The only additional color was that management expects to update investors once the MAKO results are received in early 2018.
The optimistic case is centered on the upcoming MAKO readout, which management believes is positioned to confirm the visual acuity benefits seen in the most responsive Phase 2 subgroup. They also said the trial was enriched for the patients most likely to benefit and that there is still considerable interest from potential pharma partners.
The main risk is that the company is still entirely dependent on a single clinical asset and the upcoming MAKO results, with no questions or data provided on the call beyond the setup for the readout. Management also acknowledged that not all patients are good candidates for Squalamine combination therapy, and the company’s cash runway only extends into April 2018.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 88.0%
- Shares Outstanding
- 3.75M
- Float Shares
- 3.30M
of shares held by institutions
17 13F filers
Buy/sell ratio 0.14. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Greenlight Capital Inc | 136.35K | 0 |
| Jacob Asset Management Of New York LLC | 15.65K | 0 |
Held by 1 ETFs
Biggest fund positions in NBSE by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 18, 23 | Symetryx Corp | other | 0 |
| Dec 31, 22 | Symetryx Corp | other | 0 |
| Sep 14, 23 | Symetryx Corp | sell | 129,108 |
| Sep 15, 23 | Symetryx Corp | sell | 103,337 |
| Sep 18, 23 | Symetryx Corp | sell | 50,000 |
| Aug 23, 23 | Symetryx Corp | other | 0 |
| Aug 23, 23 | Symetryx Corp | other | 0 |
| Sep 7, 23 | Symetryx Corp | sell | 74,852 |
| Sep 8, 23 | Symetryx Corp | sell | 128,847 |
| Sep 11, 23 | Symetryx Corp | sell | 3,376 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NBSE coverage
Recent articles, reports, and earnings notes.
No research on NBSE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NBSE report →NeuBase Therapeutics Announces Receipt of Notice from Nasdaq
globenewswire.com · Apr 5
Why Is NeuBase Therapeutics (NBSE) Stock Down 58% Today?
investorplace.com · Mar 26
Cheap Penny Stocks To Buy Now? 3 For Your Watch List
pennystocks.com · Sep 14
NeuBase Therapeutics Issues Statement Regarding Filing By Shareholder
globenewswire.com · Sep 8
NeuBase (NBSE) Surges 107% on New Shareholder Acquiring Stake
zacks.com · Sep 7
Why Is NeuBase Therapeutics (NBSE) Stock Down 27% Today?
investorplace.com · Sep 7
SYMETRYX CORPORATION ACQUIRES 20% STOCK IN NEUBASE
prnewswire.com · Sep 6
Why Is NeuBase Therapeutics (NBSE) Stock Up 19% Today?
investorplace.com · Sep 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.